Veriheal

DECEMBER 15, 2023

How MAPS Plans To Help MAPS has been at the forefront of psychedelic research for decades, funding studies, seminars, and conferences to promote proper education and harm reduction about a myriad of substances. If the measure passes, MDMA will make history as the first psychedelic approved for pharmaceutical use.

Therapy 109

Therapy Decriminalization Treatment Pharmaceutical 109

Cannabis Law Report

JUNE 7, 2019

The use of pharmaceutical cannabinoid products in Singapore comes under strict frameworks and regulations and does not diminish the country’s zero-tolerance position against drugs, the Home Affairs and Health ministries have said. ” At a Central Narcotics Bureau’s workplan seminar on May 24, Law and Home Affairs Minister K.

Pharmaceutical 40

Pharmaceutical Cannabinoids Safety Data 40

The Joint Blog

MAY 5, 2020

In addition to the numerous states and countries that have and are liberalizing their marijuana policies, the clear sign to this fact is that numerous major public and private universities now offer marijuana-related programs. These include short seminars, all the way to full degrees.

Medicine 26

Medicine Extraction Programs Food 26

Cannabis Law Report

DECEMBER 8, 2019

Edited by renowned endocannabinoid researcher, Jahan Marcu, PhD, AJEM’s inaugural issue was published last month in conjunction with a medical education seminar put on by Havas at Columbia University. AJEM’s mission is to create, collect, and disseminate credible cannabis research data. Federal Register. 2019;84(168):45501-45502.

Medicine 45

Medicine Research and Development Food Cannabinoids 45

Cannabis Law Report

NOVEMBER 24, 2021

These publications offer valuable indicators for current debates and disputes, political contestations, demands for reform or policy change, reactions to research activities and evidence, as well as attitudes from the medical profession towards new treatments and therapies like medicinal cannabis. upcoming seminars).

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

DECEMBER 8, 2021

In our conversation with JM, we discuss their work as Development Director for NORML, how their experiences with cancer led them to NORML, and how NORML supports its affiliate chapters that are doing grassroots work to affect public policy changes both locally and internationally. Codi Peterson: Hello, I’m Dr. Codi Peterson.

Access 104

Access Policy Patients Cannabis 104

Cannabis Law Report

DECEMBER 22, 2021

Peter advises inter alia companies in the pharmaceutical, diagnostics, biotechnology, medical device and medical cannabis industries—from startups to large publicly listed companies. He regularly holds lectures at seminars and conferences. Jelsma / International Journal of Drug Policy 23 (2012) p. Bewley-Taylor, M.

Recreational 52

Recreational Legalization Decriminalization Cultivation 52